Showing 1 - 10 of 21 records.

20110261-TVEC: A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous System Tumors That are Amenable to Direct Injection

  • Conditions: Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Neuroblastoma, Cancer - Musculoskeletal Tumors, Neuroblastoma Relapse - Refractory, Sarcoma Osteosarcoma Relapse, Sarcoma Ewing Relapse, Sarcoma Rhabdomyosarcoma Relapse, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Liver Relapse - Refractory, Kidney Relapse - Refractory, Solid Tumor Retinoblastoma Relapse - Refractory, Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory, Solid Tumor Melanoma Relapse - Refractory, Solid Tumor Germ Cell Tumor Relapse - Refractory, Solid Tumors - All Other

PURPOSE: This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection.
 DETAILED DESCRIPTION: This is a phase 1, multicenter, open-label study of talimogene ...More

ADVL0413: A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias

  • Conditions: Cancer - Kidney Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors
  • Gender: Female, Male

This phase I trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. ...More

ADVL0815: Phase I Study Pazopanib Single Agent for Solid Tumor

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Liver Tumors, Neurology
  • Gender: Female, Male

This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment. ...More

ADVL0921: A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children With Recurrent / Refractory Solid Tumors and Leukemia

  • Conditions: Cancer - Kidney Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors
  • Gender: Female, Male

This phase II trial is studying the side effects of and how well Alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. ...More

ADVL1011: A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Hemangioma and Vascular Malformation, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease.  ...More

ADVL1013: A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors
  • Gender: Female, Male

This phase I trial is studying the side effects, best way to give, and best dose of MK2206 in treating patients with recurrent or refractory solid tumors or leukemia. ...More

ADVL1111: A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND# 112603) in Children With Relapsed or Refractory Solid Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Neurofibromatosis Tumors, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ...More

ADVL1121: A Phase II trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib(IND# 69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcomas, Wilms Tumors, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma

  • Conditions: Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors
  • Gender: Female, Male

This Phase II trial will study how well sorafenib tosylate works in treating younger patients with relapsed or refractory Rhabdomyosarcoma, Wilms Tumors, Liver cancer or Thyroid cancer  ...More

ADVL1312: A Phase 1/2 Study of MK-1775 in Combination With Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Retinoblastoma, Brain Spinal Tumors Medulloblastoma Relapse, Brain Spinal Tumor Low Grade Glioma Relapse, Brain Spinal Tumor DIPG Relapse, Brain and Spinal Tumor Ependymoma Relapse, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Brain Spinal Other ATRT, Brain Spinal Other Craniopharyngioma, Brain Spinal Other Germ Cell Tumor, Brain Spinal Other Choroid Plexus Tumor, Brain Spinal Other All Other
  • Gender: Female, Male

This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the grow ...More

ADVL1414: A Phase 1 Study of Selinexor (KPT-330, IND#125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors.

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma
  • Gender: Female, Male

PURPOSE: The investigators will conduct a phase 1 trial of Selinexor in children with recurrent or refractory solid tumors, including CNS tumors using the Rolling Six design. The aims of the trial will be to establish the maximum tolerated pediatric doses of tablet formulation; to investigate ...More

Contact Us

hospital

Adult Participants or Parents of Participants:

Cincinnati Children’s is involved in research because it is very important to understanding diseases and developing ways to prevent and treat health problems in children, as well as adults. Learn more about how you can help. Contact us at clinicalstudies@cchmc.org or 513-636-0098. Or, enroll in our database to be notified about future studies by completing an online sign up form.

Sponsors and Investigators:

The Office for Clinical and Translational Research at Cincinnati Children’s provides sponsors and investigators with comprehensive support services, research tools, personnel and facilities to conduct or facilitate pediatric and adult clinical research studies. Contact us at OCTR@cchmc.org or 513-636-0314.